Tag Archives: booster

As the holiday season approaches, COVID cases are on the rise once again around the world. Globally, there have been more than 654 million COVID cases, with more than 15 million recorded in the last 28 days, according to the Johns Hopkins Coronavirus Resource Center. The U.S. is nearing an overall total of 100 million cases, with more than 1.5 million cases seen over the last 28 days. Despite this uptick, one NYC-based physician is optimistic about how the U.S. will fare throughout the winter,… Source link

The COVID-19 booster market is starting to look more like an annual flu season than it did in the first two years of the pandemic. That’s according to Moderna (MRNA) CEO Stéphane Bancel, who joined Yahoo Finance’s 2022 All Markets Summit to discuss the COVID vaccine outlook. Bancel noted that not everyone is likely to need an annual booster. “I think it’s going to be like the flu. If you’re a 25-year-old do you need an annual booster every year if you’re healthy? You might want to … but I… Source link

Last week, the Food and Drug Administration and the Centers for Disease Control and Prevention authorized a fourth dose of the COVID-19 vaccine for people 50 years and older, as well as some immunocompromised people. The decision was made at a time when COVID-19 cases and hospitalizations in the United States have been declining. At the moment, more than 99% of U.S. counties have low or medium COVID-19 community levels, according to CDC data. So why would someone need another booster at a time… Source link

By Nancy Lapid (Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review. Alzheimer’s-like changes seen in COVID-19 patients’ brains People who die of severe COVID-19 have brain abnormalities that resemble changes seen in Alzheimer’s disease – accumulation of a protein called tau inside brain cells, and abnormal amounts of the protein beta-amyloid that… Source link

While COVID-19 booster shot eligibility is continuing to expand in the U.S., not all doctors believe that’s where the focus should be in the fight against the coronavirus. “Honestly, I think that boosters right now are a bit of a distraction away from where we should be focused, which is getting first doses, especially since we know that even now, even with Delta surging, the primary doses of the vaccines are highly protective against serious infection, against hospitalization,” Dr…. Source link

Donald J. Trump joined Yahoo Finance for a wide-ranging conversation covering topics such as the U.S. economy, COVID-19 vaccines, cryptocurrencies, and his thinking on a third run for the presidency in 2024. The full interview will be released on Monday. Former President Donald Trump has revealed which COVID-19 vaccine he received before leaving the White House.   “Well, I got the Pfizer and I would have been very happy with any of them,” Trump told Yahoo Finance Live in a wide-ranging… Source link

Johnson & Johnson (JNJ) announced promising booster data Tuesday showing 94% efficacy for its COVID-19 vaccine when given after six months of the initial dose. In addition, the initial dose of the vaccine continued to provide consistent protection against the virus, including against the Delta variant, the company said in a statement. The latter news puts the vaccine in stark contrast to mRNA vaccines, which have shown waning immunity over time. Mathai Mammen, J&J’s global head of R&D, told… Source link

The FDA rejected Pfizer (PFE)/BioNTech’s (BNTX) booster shot recommendation for the general public in order to place greater focus on inoculating the unvaccinated populations and collecting more data on booster shots, Meghan FitzGerald, adjunct associate professor of health policy and management at Columbia University, told Yahoo Finance Live. Though the FDA rejected the booster for the general public by a large margin (16-2), the shot was endorsed unanimously for the elderly and… Source link

A U.S. Food and Drug Administration (FDA) advisory panel voted Friday against approval of Pfizer (PFE)/BioNTech’s (BNTX) third dose for the U.S. The vote comes after a heated debate in recent weeks over the need for booster or additional shots, which both mRNA companies — Pfizer and Moderna (MRNA) — have advocated for. Dr. Peter Marks, the FDA’s leading expert on vaccines, touched on the controversy in his introductory remarks. “We know that there may be differing opinions of the… Source link

Amid the growing controversy over whether the U.S. is in need of booster or additional vaccine doses to protect against COVID-19, Moderna (MRNA) president Stephen Hoge admits much remains unknown. “We don’t really know” if a third shot will be the final or if more are needed, Hoge told Yahoo Finance. In addition, whether or not the third shot is needed is a question. “It’s the “key scientific question we’re all wrestling with now,” Hoge said. If an additional does does prove to provide some… Source link